Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Page 1
Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus.
Martinovic J, Samardzic J, Zaric Kontic M, Ivkovic S, Dacic S, Major T, Radosavljevic M, Svob Strac D. Martinovic J, et al. Among authors: dacic s. Brain Sci. 2023 Dec 12;13(12):1707. doi: 10.3390/brainsci13121707. Brain Sci. 2023. PMID: 38137155 Free PMC article.
Zaleplon is a positive allosteric modulator of the gamma-aminobutyric acid (GABA)(A) receptor approved for the short-term treatment of insomnia. Previous publications on zaleplon have not addressed the proteins involved in its mechanism of action but have mostly referred t …
Zaleplon is a positive allosteric modulator of the gamma-aminobutyric acid (GABA)(A) receptor approved for the short-term treatment o …
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
Dacic S, Travis WD, Giltnane JM, Kos F, Abel J, Hilz S, Fujimoto J, Sholl L, Ritter J, Khalil F, Liu Y, Taylor-Weiner A, Resnick M, Yu H, Hirsch FR, Bunn PA Jr, Carbone DP, Rusch V, Kwiatkowski DJ, Johnson BE, Lee JM, Hennek SR, Wapinski I, Nicholas A, Johnson A, Schulze K, Kris MG, Wistuba II. Dacic S, et al. J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415-2. doi: 10.1016/j.jtho.2023.12.010. Online ahead of print. J Thorac Oncol. 2023. PMID: 38070597
INTRODUCTION: Pathologic response (PathR) by histopathologic assessment of resected specimens may be an early clinical end point associated with long-term outcomes with neoadjuvant therapy. Digital pathology may improve the efficiency and precision of PathR assessment. ... …
INTRODUCTION: Pathologic response (PathR) by histopathologic assessment of resected specimens may be an early clinical end point associated …
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, Husain AN, Kadota K, Khoor A, Nicholson AG, Roggli V, Schmitt F, Tsao MS, Travis WD. Sauter JL, et al. Among authors: dacic s. J Thorac Oncol. 2022 May;17(5):608-622. doi: 10.1016/j.jtho.2021.12.014. Epub 2022 Jan 10. J Thorac Oncol. 2022. PMID: 35026477 Free article. Review.
Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the following: (1) pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified wit …
Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include the fol …
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I; WHO Panel. Travis WD, et al. Among authors: dacic s. J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630. J Thorac Oncol. 2015. PMID: 26291008 Free article.
The most significant changes in this edition involve (1) use of immunohistochemistry throughout the classification, (2) a new emphasis on genetic studies, in particular, integration of molecular testing to help personalize treatment strategies for advanced lung cancer patients, ( …
The most significant changes in this edition involve (1) use of immunohistochemistry throughout the classification, (2) a new emphasis on ge …
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Argiris A, et al. Among authors: dacic s. J Clin Oncol. 2010 Dec 20;28(36):5294-300. doi: 10.1200/JCO.2010.30.6423. Epub 2010 Nov 15. J Clin Oncol. 2010. PMID: 21079141 Free PMC article.
CONCLUSION: This cetuximab-containing regimen resulted in excellent long-term survival and safety, and warrants further evaluation in both HPV-positive and -negative HNC....
CONCLUSION: This cetuximab-containing regimen resulted in excellent long-term survival and safety, and warrants further evaluation in …
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle P, Popper H. Dacic S, et al. Virchows Arch. 2008 Dec;453(6):627-35. doi: 10.1007/s00428-008-0689-3. Epub 2008 Oct 29. Virchows Arch. 2008. PMID: 18958493
Our study is the first to demonstrate decreased frequency of homozygous deletion of 9p21 and loss of p16 immunoreactivity in pleural mesotheliomas from patients with long-term survival of greater than 3 years in contrast to patients with rapidly fatal mesotheliomas. ...
Our study is the first to demonstrate decreased frequency of homozygous deletion of 9p21 and loss of p16 immunoreactivity in pleural mesothe …